Stayble Therapeutics AB (STABL) — Cash Flow-to-Debt Ratio
Stayble Therapeutics AB (STABL) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of Skr-1.34 Million could theoretically repay -1% of its total liabilities (Skr1.70 Million) in one year. Check how aggressively does Stayble Therapeutics AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Stayble Therapeutics AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Stayble Therapeutics AB across 10 annual periods. Also explore balance sheet size of Stayble Therapeutics AB for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Stayble Therapeutics AB (2016–2025)
Year-by-year debt coverage analysis for Stayble Therapeutics AB. For market capitalisation and broader financial context, see Stayble Therapeutics AB (STABL) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.96x | Skr-6.72 Million | Skr1.70 Million | ▲ +35.7% |
| 2024 | -6.15x | Skr-14.67 Million | Skr2.38 Million | ▼ -35.8% |
| 2023 | -4.53x | Skr-23.54 Million | Skr5.19 Million | ▲ +29.6% |
| 2022 | -6.44x | Skr-24.89 Million | Skr3.87 Million | ▼ -156.0% |
| 2021 | -2.51x | Skr-9.63 Million | Skr3.83 Million | ▲ +74.3% |
| 2020 | -9.80x | Skr-23.98 Million | Skr2.45 Million | ▼ -33999.6% |
| 2019 | 0.03x | Skr289.39K | Skr10.01 Million | ▲ +101.0% |
| 2018 | -2.87x | Skr-5.42 Million | Skr1.89 Million | ▼ -32.9% |
| 2017 | -2.16x | Skr-2.62 Million | Skr1.21 Million | ▼ -70.5% |
| 2016 | -1.27x | Skr-1.39 Million | Skr1.10 Million | — |